1. Knockdown of Hyaluronan synthase 2 suppresses liver fibrosis in mice via induction of transcriptomic changes similar to 4MU treatment.
- Author
-
Halimani N, Nesterchuk M, Tsitrina AA, Sabirov M, Andreichenko IN, Dashenkova NO, Petrova E, Kulikov AM, Zatsepin TS, Romanov RA, Mikaelyan AS, and Kotelevtsev YV
- Subjects
- Animals, Mice, Gene Expression Profiling, Hyaluronan Synthases genetics, Hyaluronan Synthases metabolism, Liver Cirrhosis chemically induced, Liver Cirrhosis drug therapy, Liver Cirrhosis genetics, RNA, Small Interfering, Hyaluronic Acid metabolism, Hymecromone pharmacology
- Abstract
Hepatic fibrosis remains a significant clinical challenge due to ineffective treatments. 4-methylumbelliferone (4MU), a hyaluronic acid (HA) synthesis inhibitor, has proven safe in phase one clinical trials. In this study, we aimed to ameliorate liver fibrosis by inhibiting HA synthesis. We compared two groups of mice with CCl
4 -induced fibrosis, treated with 4-methylumbelliferone (4MU) and hyaluronan synthase 2 (HAS2) targeting siRNA (siHAS2). The administration of 4MU and siHAS2 significantly reduced collagen and HA deposition, as well as biochemical markers of hepatic damage induced by repeated CCl4 injections. The transcriptomic analysis revealed converging pathways associated with downstream HA signalling. 4MU- and siHAS2-treated fibrotic livers shared 405 upregulated and 628 downregulated genes. These genes were associated with xenobiotic and cholesterol metabolism, mitosis, endoplasmic reticulum stress, RNA processing, and myeloid cell migration. The functional annotation of differentially expressed genes (DEGs) in siHAS2-treated mice revealed attenuation of extracellular matrix-associated pathways. In comparison, in the 4MU-treated group, DEGs were related to lipid and bile metabolism pathways and cell cycle. These findings confirm that HAS2 is an important pharmacological target for suppressing hepatic fibrosis using siRNA., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF